Seaport Therapeutics, Inc. (SPTX) Income Statement
SPTX 2025 at a glance
Fiscal year ended December 31, 2025 · U.S. dollarsSPTX revenue and net income
SPTX growth rates
to 2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | — | — | — | — |
| Operating income | — | — | — | — |
| Net income | — | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
SPTX quarterly EPS vs estimates
Seaport Therapeutics beat the analyst EPS estimate in 0 of the last 2 quarters. Next report: November 2, 2026 (estimate $-0.58).
SPTX income statement
| 2025 | 2024 | |
|---|---|---|
| Revenue | $0 | $0 |
| Research & development | $66.3M | $25.1M |
| Sales, general & admin | $21.0M | $27.3M |
| Total operating expenses | $87.3M | $52.4M |
| Operating income | −$87.3M | −$52.4M |
| Interest income | $11.4M | $5.5M |
| Income before taxes | −$74.1M | −$46.9M |
| Income taxes | $773,000 | — |
| Net income | −$74.9M | −$46.9M |
| EBITDA | −$85.9M | −$52.2M |
| Jun '26 | Mar '26 | Mar '25 | |
|---|---|---|---|
| Revenue | $0 | $0 | $0 |
| Cost of revenue | $351,000 | — | — |
| Gross profit | −$351,000 | — | — |
| Research & development | $24.6M | $21.4M | $10.5M |
| Sales, general & admin | — | $6.1M | $5.7M |
| Total operating expenses | $65.5M | $27.5M | $16.2M |
| Operating income | −$65.8M | −$27.5M | −$16.2M |
| Interest income | — | $2.1M | $3.1M |
| Income before taxes | −$62.6M | −$24.9M | −$13.1M |
| Income taxes | $15,000 | $519,000 | — |
| Net income | −$62.6M | −$25.4M | −$13.1M |
| EBITDA | −$65.5M | −$27.2M | −$15.9M |
| EPS (diluted) | −$1.78 | −$10.34 | — |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in SPTX's financial statements (latest annual report filed December 31, 2025); data from EODHD. Sales, general & administrative expenses include sales and marketing.
SPTX financial results
Seaport Therapeutics reported no revenue in fiscal year 2025 (ended December 31, 2025). It had a net loss of $74.9 million.
See the SPTX stock overview for the latest quote and news, or the SPTX chart for price history and technical indicators.
SPTX income statement FAQ
Does Seaport Therapeutics have revenue?
Seaport Therapeutics reported no revenue for fiscal year 2025, which ended on December 31, 2025.
Is Seaport Therapeutics profitable?
No. Seaport Therapeutics reported a net loss of $74.9 million in fiscal 2025.
How much does Seaport Therapeutics spend on research and development?
Seaport Therapeutics spent $66.3 million on research and development in fiscal 2025.
When will Seaport Therapeutics report its next earnings?
Seaport Therapeutics is expected to report results for the quarter ending September 30, 2026 on November 2, 2026.
When does Seaport Therapeutics's fiscal year end?
Seaport Therapeutics's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025 and was filed on December 31, 2025.